Oral dIuretics in Very Intensive Treatment, an Early Intervention in Outpatients With Heart Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-10-15

Study Completion Date

2019-10-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the present study, consecutive patients, older than 18 years, of both genders will be included. The diagnosis of reduced Heart Failure (HfrEF) according to: Clinical pattern, laboratories and Cardiac imaging (ESC criteria). Treatment will be assigned in two groups: Bumetanide and another group will be received Indapamide. Each group received maximum tolerated dose for seven days with Clinical and labs evaluations will be every 48 hrs. (Face-to-face and/or telephone visits). Serum and urinary labs, EKG´s, Echo will be evaluated. Daily in-home register will made. Final points were: Mortality, Urinary failure, Clinical Impairment, Hospital admissions, Oedema. (MUCHO). All patients will be followed for 30 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bumetanide Versus Furosemide in Heart Failure

NCT00372762

Heart Failure

WITHDRAWN PHASE3

Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure

NCT01644331

Heart Failure Dyspnea

COMPLETED PHASE3

Prolonged Intravenous Therapy Versus Early Initiation of an Oral Loop Diuretic in Decompensated Heart Failure

NCT05652322

Heart Failure

WITHDRAWN PHASE2/PHASE3

Sub-Q Versus IV Furosemide in Acute Heart Failure

NCT02579057

Congestive Heart Failure

COMPLETED PHASE2/PHASE3

A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

NCT04157751

Heart Failure

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In selected patients who sign informed consent with decompensation of cardiac failure by water congestion will be allocated in two groups: Bumetanide and the other Indapamide group. Each group will be given the maximum tolerated dose for seven days with clinical evaluations every 48 hours. (Face to face and/or telephone). Clinical variables, ECG and serum and urine laboratories will be assessed finally, patients will follow up for 30 days. To identify endpoints such as: mortality, urinary failure, clinical deterioration, hospital admissions, edema. (MUCHO).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Congestive Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BUMETANIDE

we will administrated bumetanide at dosis: oral, 2mg each 8hours for seven day.

Group Type EXPERIMENTAL

Bumetanide 1 MG

Intervention Type DRUG

all patients will be taking the treatment recommended by heart failure guidelines

INDAPAMIDE

we will administrated indapamide at dosis:oral,1.5MG each 8hours for seven day.

Group Type ACTIVE_COMPARATOR

Bumetanide 1 MG

Intervention Type DRUG

all patients will be taking the treatment recommended by heart failure guidelines

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bumetanide 1 MG

all patients will be taking the treatment recommended by heart failure guidelines

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

heart failure guidelines treatment

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Older over 18 year 2. Both gender. 3. Patients are able to read, write and understand. 4.-Heart failure criteria:a) Clinical signs and symptoms b) serum NTP-proBNP: over 125pg/ml. or serum bnp: over: 35pg/ml. c) Left ventricular ejection fraction under 40% ( By any image study: echocardiogram, Tomography , MRI,Nuclear medicine.) 5. Commitment to participate in the follow-up of the present study.

Exclusion Criteria

1. Pregnant or lactating women.
2. Patients with deterioration of their clinical condition that warrant rapid attention by the emergency department.
3. Patients with symptomatic hypotension by arterial pressure over; 90/50 mmHg.
4. Symptomatic heart rate disorders: tachycardia greater than 120 beats per minute or bradycardia less than 50 beats per minute.
5. Patients with respiratory impairment: by tachypnea (respiratory rate greater than 22 per min), peripheral oxygen saturation less than 90%.
6. Clinical signs or by methods of pleural effusion image that compromise the ventilatory mechanism.
7. Hormonal thyroid decontrol (thyroid hormone profile outside the reference range)
8. Serum glucose numbers greater than 140mg/DL and/or glycosylated hemoglobin greater than 6.5%.
9. Renal damage characterized by serum creatinine numbers greater than 1.5 mg/DL.
10. Alteration of the hepatic test: serum aspartate aminotransferase and/or serum alanine aminotransferase by levels greater than three times the upper limit of reference.
11. Alterations in serum electrolytes (by sodium greater 135 mmol/L or less 145 mmol; Potassium less than 3.5 mmol/L or higher 5.35 mmol/L)
12. Intolerance or allergy recognized for any diuretic.
13. Comorbidities that prevent the follow-up of treatment: (Alcoholism, drug addiction, psychiatric disorders)
14. Positive serology carriers for Hepatitis (B, C) HIV.
15. Acute myocardial infarction (with and without elevation) in the last three months.
16. History of vascular (ischemic or hemorrhagic) brain disease in the last three months.
17. Carriers of acute inflammatory and/or immunologic disease in the last three months (e.g. Active Lupus etc.)
18. Active myocarditis in the last three months
19. History of Prostatism, or recognized prostatic alterations, that impede voiding flow.
20. Terminal cancer
21. Blunt physical and cognitive deterioration that prevents optimal follow-up.
22. Cultural barriers involving limitation of communication (languages, dialects, reading and writing, etc.).
23. Not to sign informed consent

\-

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No